Direct cord robust optimization preserved target coverage near the spinal cord
In ten paraspinal chordoma plans, direct cord robust optimization improved coverage and robustness while maintaining acceptable spinal cord doses.
In ten paraspinal chordoma plans, direct cord robust optimization improved coverage and robustness while maintaining acceptable spinal cord doses.
A score above seven identified patients with treatment beyond 56 days in 53.6% versus 17.8% at lower scores.
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
Simulated proton minibeams preserved spatial fractionation and target homogeneity for targets up to 20 centimetres with depth-adapted beam widths and spacing.
Carbon fiber-reinforced polyetheretherketone implants consistently reduced imaging artifacts and dosimetric uncertainty versus titanium, but clinical outcome evidence remains limited.
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
After 66% of couch-angle changes, motion exceeded tolerance, and 0.5-millimetre and 0.5-degree errors reduced near-minimum target dose by 7.6%.
Combined high lactate dehydrogenase-5 expression and low tumor-infiltrating lymphocyte density independently identified higher biochemical relapse risk after prostate radiotherapy.
Adding pan-mucosal irradiation did not improve survival or reduce mucosal recurrence compared with nodal-only irradiation in thoroughly staged head and neck unknown primary cancer.
Across 500 clinical cases, automated planning preserved target coverage and was associated with lower doses to multiple critical structures than earlier manual planning.
After 13 years, first-line temozolomide and radiotherapy produced similar progression-free and overall survival across molecularly classified low-grade gliomas.
Across 1,760 patients, most grade 3 adverse events remained below 1.5%, although post-prostatectomy urinary incontinence reached 10.2% by eight years.
Three of four patients completed final imaging and lung stereotactic ablative radiotherapy within one assisted breath-hold, with only grade 1 adverse events.
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Mean breast target displacement was below 1.3 mm in every direction, with calculated respiratory margins of approximately 1 mm.